These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25245943)

  • 1. Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.
    Schipani A; Back D; Owen A; Davies G; Khoo S; Siccardi M
    Clin Pharmacokinet; 2015 Jan; 54(1):107-16. PubMed ID: 25245943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching safely: pharmacokinetics, efficacy and safety of switching efavirenz to maraviroc twice daily in patients on suppressive antiretroviral therapy.
    Waters L; Jackson A; Else L; Rockwood N; Newell S; Back D; Nelson M; Gazzard B; Boffito M
    Antivir Ther; 2015; 20(2):157-63. PubMed ID: 24963558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.
    Siccardi M; Marzolini C; Seden K; Almond L; Kirov A; Khoo S; Owen A; Back D
    Clin Pharmacokinet; 2013 Jul; 52(7):583-92. PubMed ID: 23479398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.
    Stöhr W; Back D; Dunn D; Sabin C; Winston A; Gilson R; Pillay D; Hill T; Ainsworth J; Pozniak A; Leen C; Bansi L; Fisher M; Orkin C; Anderson J; Johnson M; Easterbrook P; Gibbons S; Khoo S; ;
    Antivir Ther; 2008; 13(5):675-85. PubMed ID: 18771051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of efavirenz and nevirapine among HIV-infected patients with immunological failure attending a tertiary hospital in North-western Tanzania.
    Gunda DW; Kasang C; Kidenya BR; Kabangila R; Mshana SE; Kidola J; Kalluvya SE; Kongola GW; Klinker H
    PLoS One; 2013; 8(9):e75118. PubMed ID: 24058655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
    Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
    Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study.
    Taiwo B; Acosta EP; Ryscavage P; Berzins B; Lu D; Lalezari J; Castro J; Adeyemi O; Kuritzkes DR; Eron JJ; Tsibris A; Swindells S
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):167-73. PubMed ID: 23797691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings.
    Cooper DA; Heera J; Ive P; Botes M; Dejesus E; Burnside R; Clumeck N; Walmsley S; Lazzarin A; Mukwaya G; Saag M; van Der Ryst E
    AIDS; 2014 Mar; 28(5):717-25. PubMed ID: 24983542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients.
    Funderburg N; Kalinowska M; Eason J; Goodrich J; Heera J; Mayer H; Rajicic N; Valdez H; Lederman MM
    PLoS One; 2010 Oct; 5(10):e13188. PubMed ID: 20949133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
    Kappelhoff BS; van Leth F; MacGregor TR; Lange J; Beijnen JH; Huitema AD;
    Antivir Ther; 2005; 10(1):145-55. PubMed ID: 15751772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.
    Dlamini JN; Hu Z; Somaroo H; Highbarger HC; Follmann DA; Dewar RL; Pau AK
    Pharmacotherapy; 2011 Feb; 31(2):158-63. PubMed ID: 21275494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc Population Pharmacokinetics Within the First 6 Weeks of Life.
    Liyanage M; Nikanjam M; McFadyen L; Vourvahis M; Rogg L; Moye J; Chadwick EG; Jean-Philippe P; Mirochnick M; Whitson K; Bradford S; Capparelli EV; Best BM
    Pediatr Infect Dis J; 2022 Nov; 41(11):885-890. PubMed ID: 35980827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moving away from Ritonavir, Abacavir, Tenofovir, and Efavirenz (RATE)--agents that concern prescribers and patients: a feasibility study and call for a trial.
    Achhra AC; Boyd MA; Law MG; Matthews GV; Kelleher AD; Cooper DA
    PLoS One; 2014; 9(6):e99530. PubMed ID: 24968324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.
    Pozniak AL; Boffito M; Russell D; Ridgway CE; Muirhead GJ
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):54-9. PubMed ID: 18333866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment.
    Maganda BA; Ngaimisi E; Kamuhabwa AA; Aklillu E; Minzi OM
    Malar J; 2015 Apr; 14():179. PubMed ID: 25906774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic effects of coadministration of lersivirine with raltegravir or maraviroc in healthy subjects.
    Vourvahis M; Langdon G; Labadie RR; Layton G; Ndongo MN; Banerjee S; Davis J
    Antimicrob Agents Chemother; 2012 Feb; 56(2):887-92. PubMed ID: 22123705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
    Else LJ; Taylor S; Back DJ; Khoo SH
    Antivir Ther; 2011; 16(8):1139-47. PubMed ID: 22155898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study.
    van Leth F; Phanuphak P; Ruxrungtham K; Baraldi E; Miller S; Gazzard B; Cahn P; Lalloo UG; van der Westhuizen IP; Malan DR; Johnson MA; Santos BR; Mulcahy F; Wood R; Levi GC; Reboredo G; Squires K; Cassetti I; Petit D; Raffi F; Katlama C; Murphy RL; Horban A; Dam JP; Hassink E; van Leeuwen R; Robinson P; Wit FW; Lange JM;
    Lancet; 2004 Apr; 363(9417):1253-63. PubMed ID: 15094269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
    Veldkamp AI; Harris M; Montaner JS; Moyle G; Gazzard B; Youle M; Johnson M; Kwakkelstein MO; Carlier H; van Leeuwen R; Beijnen JH; Lange JM; Reiss P; Hoetelmans RM
    J Infect Dis; 2001 Jul; 184(1):37-42. PubMed ID: 11398107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effectiveness of first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy in Ghana.
    Sarfo FS; Sarfo MA; Kasim A; Phillips R; Booth M; Chadwick D
    J Antimicrob Chemother; 2014 Jan; 69(1):254-61. PubMed ID: 24003181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.